AstraZeneca Shares Are Down 1.7% Due To The Suspension Of COVID Vaccine Trials
Shares of the British-Swedish pharmaceutical company AstraZeneca are down 1.69% on the London stock exchange (LSE) after reports that it suspended testing of a coronavirus vaccine, according to data from the trading platform.
As of 17.08 GMT, securities were losing 1.69% in price, falling to 82.07 pounds. At the same time, the main index of the British stock market FTSE 100 on Wednesday is trading in the "green" zone.
Clinical trials of AstraZeneca's coronavirus vaccine have been suspended due to a possible adverse effect in one of the participants from the UK. A representative of the company said that AstraZeneca intends to speed up the analysis of this case to minimize the possible impact on the timing of the tests. According to the representative, the suspension of testing is routine and necessary in such cases. It's unclear yet how long the suspension of clinical trials will last.
On Wednesday, it was announced that AstraZeneca had suspended clinical trials of the vaccine in Japan. The AstraZeneca vaccine, which is being developed together with Oxford specialists, moved to the third phase of trials in the United States in August. Earlier, AstraZeneca tests began in the UK, Brazil, and South Africa. The company is developing a vaccine based on monkey adenovirus vectors.